Quantcast

Latest Mapatumumab Stories

2011-08-26 07:00:00

Premiere Oncology today announced that it is participating in a Phase 2b/3 clinical trial of ganetespib, a novel, potent anti-cancer drug in combination with docetaxel, an approved chemotherapy drug, for the treatment of non-small cell lung cancer patients. Santa Monica, CA (PRWEB) August 26, 2011 Ganetespib is the most advanced drug candidate in a new class of anti-cancer drugs called heat shock protein (Hsp) 90 inhibitors. Hsp90 is a molecular chaperone required for the proper folding...

2011-08-19 13:52:00

SILVER SPRING, Md., Aug. 19, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Lymphomas are cancers of the lymphatic system. Adcetris is an antibody-drug conjugate that combines an antibody and drug, allowing the antibody to direct the drug to a target on...

2011-06-08 08:09:00

CALGARY, June 8, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC), (NASDAQ:ONCY) ("Oncolytics") today announced that an abstract covering interim preliminary results from a Phase 2 clinical trial using intravenous administration of REOLYSIN(® )in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours is available on the International Association for the Study of Lung Cancer World...

2011-06-06 08:00:00

LONDON, June 6, 2011 /PRNewswire-FirstCall/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, announces positive updated data from its ongoing Phase I study of Atu027, one of the most clinically advanced RNAi therapeutics in the area of oncology, in patients with advanced solid tumors. Study results show that nine of the 24 patients treated with Atu027 to date achieved stable disease after repeated treatment...

2011-06-03 12:39:40

Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy. Reported in the journal Clinical Cancer Research, the study determined the maximum tolerated dose with acceptable side effects for this novel drug combination. The trial...

2011-06-02 08:08:00

NEW YORK, June 2, 2011 /PRNewswire/ -- Citeline, the world's leading research authority on pharmaceutical clinical trials and intelligence recently completed a comprehensive review of clinical trial starts in the oncology therapeutic area to uncover trends and patterns in drug development. Over the one-year review period (October 2009 through September 2010) over 400 late stage trials were initiated in the oncology sector, more than any other therapeutic area, according to Citeline...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related